BR112023001861A2 - Composições e métodos para tratamento de doenças e distúrbios - Google Patents
Composições e métodos para tratamento de doenças e distúrbiosInfo
- Publication number
- BR112023001861A2 BR112023001861A2 BR112023001861A BR112023001861A BR112023001861A2 BR 112023001861 A2 BR112023001861 A2 BR 112023001861A2 BR 112023001861 A BR112023001861 A BR 112023001861A BR 112023001861 A BR112023001861 A BR 112023001861A BR 112023001861 A2 BR112023001861 A2 BR 112023001861A2
- Authority
- BR
- Brazil
- Prior art keywords
- disorders
- diseases
- methods
- compositions
- treatment
- Prior art date
Links
- 208000037765 diseases and disorders Diseases 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 2
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 abstract 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063060413P | 2020-08-03 | 2020-08-03 | |
| US202063115312P | 2020-11-18 | 2020-11-18 | |
| PCT/US2021/030192 WO2022031330A1 (en) | 2020-08-03 | 2021-04-30 | Compositions and methods for treating diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023001861A2 true BR112023001861A2 (pt) | 2023-03-07 |
Family
ID=80117618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023001861A BR112023001861A2 (pt) | 2020-08-03 | 2021-04-30 | Composições e métodos para tratamento de doenças e distúrbios |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230310444A1 (https=) |
| EP (1) | EP4188368A4 (https=) |
| JP (1) | JP2023537477A (https=) |
| KR (1) | KR20230048358A (https=) |
| CN (1) | CN116419752A (https=) |
| AU (1) | AU2021321350A1 (https=) |
| BR (1) | BR112023001861A2 (https=) |
| CA (1) | CA3188171A1 (https=) |
| CU (1) | CU20230009A7 (https=) |
| IL (1) | IL300310A (https=) |
| MX (1) | MX2023001296A (https=) |
| WO (1) | WO2022031330A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3466955T (lt) | 2014-01-13 | 2021-02-25 | Aurigene Discovery Technologies Limited | Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas |
| EP4319750A4 (en) | 2021-04-08 | 2025-02-26 | Curis, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| WO2023172640A1 (en) * | 2022-03-08 | 2023-09-14 | X4 Pharmaceuticals, Inc. | Treatments for single-mutant waldenström's macroglobulinemia |
| JP2025516501A (ja) * | 2022-05-11 | 2025-05-30 | キュリス，インコーポレイテッド | Ｉｒａｋ４修飾化合物による疾患及び障害の治療 |
| WO2024027750A1 (en) * | 2022-08-02 | 2024-02-08 | Beigene Switzerland Gmbh | Methods of treating pulmonary hypertension using btk inhibitors |
| WO2025208000A1 (en) * | 2024-03-29 | 2025-10-02 | Curis, Inc. | Methods of treating cancer in patients with altered protein expression |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3466955T (lt) * | 2014-01-13 | 2021-02-25 | Aurigene Discovery Technologies Limited | Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas |
| TW201701879A (zh) * | 2015-04-30 | 2017-01-16 | 拜耳製藥公司 | Ｉｒａｋ４抑制劑組合 |
| US20170035881A1 (en) * | 2015-10-19 | 2017-02-09 | Acerta Pharma B.V. | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor |
| EP3600270B1 (en) * | 2017-03-31 | 2023-06-14 | Aurigene Oncology Limited | Compounds and compositions for treating hematological disorders |
| HUE067356T2 (hu) * | 2017-10-31 | 2024-10-28 | Curis Inc | IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra |
| EP3800188A1 (en) * | 2019-10-02 | 2021-04-07 | Bayer AG | Substituted pyrazolopyrimidines as irak4 inhibitors |
| MX2023005591A (es) * | 2020-11-18 | 2023-05-29 | Curis Inc | Metodos de tratamiento de enfermedades y trastornos. |
| EP4319750A4 (en) * | 2021-04-08 | 2025-02-26 | Curis, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
-
2021
- 2021-04-30 IL IL300310A patent/IL300310A/en unknown
- 2021-04-30 CA CA3188171A patent/CA3188171A1/en active Pending
- 2021-04-30 BR BR112023001861A patent/BR112023001861A2/pt unknown
- 2021-04-30 CN CN202180057734.1A patent/CN116419752A/zh active Pending
- 2021-04-30 JP JP2023507267A patent/JP2023537477A/ja active Pending
- 2021-04-30 KR KR1020237007466A patent/KR20230048358A/ko active Pending
- 2021-04-30 CU CU2023000009A patent/CU20230009A7/es unknown
- 2021-04-30 EP EP21852519.4A patent/EP4188368A4/en active Pending
- 2021-04-30 AU AU2021321350A patent/AU2021321350A1/en active Pending
- 2021-04-30 MX MX2023001296A patent/MX2023001296A/es unknown
- 2021-04-30 WO PCT/US2021/030192 patent/WO2022031330A1/en not_active Ceased
- 2021-04-30 US US18/019,400 patent/US20230310444A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230310444A1 (en) | 2023-10-05 |
| CA3188171A1 (en) | 2022-02-10 |
| CN116419752A (zh) | 2023-07-11 |
| CU20230009A7 (es) | 2023-09-07 |
| WO2022031330A1 (en) | 2022-02-10 |
| EP4188368A4 (en) | 2024-09-04 |
| JP2023537477A (ja) | 2023-09-01 |
| KR20230048358A (ko) | 2023-04-11 |
| AU2021321350A1 (en) | 2023-03-16 |
| MX2023001296A (es) | 2023-02-22 |
| EP4188368A1 (en) | 2023-06-07 |
| IL300310A (en) | 2023-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023001861A2 (pt) | Composições e métodos para tratamento de doenças e distúrbios | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| DOP2023000252A (es) | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 | |
| MX2021009246A (es) | Inmunomoduladores, composiciones y metodos de los mismos. | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| BR112022012594A2 (pt) | Dosagem de gama-hidroxibutirato (ghb) | |
| BR112021006229A2 (pt) | composto, composição farmacêutica, e, método para tratamento de um câncer | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| BR112022015416A2 (pt) | Anticorpos anti-ror1 e composições | |
| CO2021015264A2 (es) | Inhibidores de dihidroorotato deshidrogenasa | |
| BR112017023740A2 (pt) | ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida? | |
| BR112017004704A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo | |
| BR112015022096A2 (pt) | moduladores de canal de sódio para o tratamento da dor | |
| BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| BR112012014990A2 (pt) | composto, método para tratar uma doença ou condição dependente de calicreína de plasma, e, composição. | |
| BR112023019211A2 (pt) | Inibidores de inflamassoma nlrp3 | |
| BR112021026820A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl) | |
| BR112023020669A2 (pt) | Terapias de combinação para o tratamento de câncer | |
| MX2022006176A (es) | Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2. | |
| BR112022003768A2 (pt) | Compostos inibidores de perk | |
| MX2021004134A (es) | Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas. | |
| EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
| BR112016020556A8 (pt) | compostos, composição farmacêutica, método de modulação da atividade do receptor de grelina, método para o tratamento de uma doença e usos de um composto | |
| BR112018000589A2 (pt) | composição de tratamento de cabelo, método para o tratamento de cabelo e utilização de uma composição |